The key to unraveling the mystery of mortality in heart failure: An integrated approach

Circulation

Volumn 107, Issue 13, 2003, Pages 1719-1721

  Deedwania, Prakash C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Death, sudden; Editorials; Heart failure; Risk factors; Survival

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; NORADRENALIN; SPIRONOLACTONE; VASODILATOR AGENT;

CARDIOVASCULAR DISEASE; DEMOGRAPHY; EDITORIAL; ELECTROCARDIOGRAM; EXERCISE TEST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INDEX; HEART RATE; HEART VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HIGH RISK PATIENT; HUMAN; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SUDDEN DEATH; VASCULAR RESISTANCE;

ATRIAL NATRIURETIC FACTOR; ELECTROCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK FACTORS;

EID: 0037426419     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000014688.12415.C0     Document Type: Editorial

References (11)

1. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex: American Heart Association; 2002.
2. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator studies. Cardiac Arrest Study Hamburg Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-2078.
3. Gold MR, Nisam S. Multicenter Automatic Defibrillator Implantation Trial. Multicenter Unsustained Tachycardia Trial. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol. 2000;23:1981-1985.
4. Louis AA, Manousos IR, Coletta AP, et al. Clinical trials update: the Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MEDIT II and REMATCH. Eur J Heart Fail. 2002;4:111-116.
5. c interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003;107:1764-1769.
6. Eichhorn EJ. Prognosis determination in heart failure. Am J Med. 2001; 110(7A):14S-36S.
7. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure: Captopril-Digoxin Study Group. J Am Coll Cardiol. 1989;14:564-570.
8. Doval HC, Nul DR, Grancelli HO, for the GESICA-GEMA investigators. Nonsustained ventricular tachycardia in severe heart failure: independent marker of increased mortality due to sudden death. Circulation. 1996;94: 3198-3203.
9. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure. What's next? Circulation. 2002;105:2328-2331.
10. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105: 2392-2397.
11. Brooksby P, Batin PD, Nolan J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure: the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Eur Heart J. 1999;20:1335-1341.